{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T19:25:46Z","timestamp":1791401146638,"version":"4.3.3"},"reference-count":32,"publisher":"SAGE Publications","issue":"1-2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HAB"],"published-print":{"date-parts":[[2017,2,20]]},"DOI":"10.3233\/hab-160300","type":"journal-article","created":{"date-parts":[[2016,10,25]],"date-time":"2016-10-25T10:46:22Z","timestamp":1477392382000},"page":"1-16","source":"Crossref","is-referenced-by-count":13,"title":["Of patents and patent disputes: The TNF\u03b1 patent files. Part 1: Humira"],"prefix":"10.1177","volume":"25","author":[{"given":"Ulrich","family":"Storz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/HAB-160300_ref1","unstructured":"Data provided by Global Sales Inc., UCB and J&J."},{"key":"10.3233\/HAB-160300_ref3","unstructured":"GaBI Online - Biosimilars of adalimumab [www.gabionline. net]. Mol, Belgium: Pro Pharma Communications International; [cited 2016 Aug 1]. Available at: http:\/\/www.gabion- line.net\/Biosimilars\/General\/Biosimilars-of-adalimumab."},{"key":"10.3233\/HAB-160300_ref4","unstructured":"Storz U., IP issues of therapeutic antibodies, in: Intellectual Property Issues: Therapeutics, Vaccines and Molecular Diagnostics, Storz U., Flasche W. and Driehaus J., eds, Springer."},{"issue":"10","key":"10.3233\/HAB-160300_ref5","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1093\/jiplp\/jpr127","article-title":"Claims to antibodies not adequately described by disclosing known antigens to which they bind","volume":"6","author":"Xue","year":"2011","journal-title":"J Intellect Prop Law Pract"},{"key":"10.3233\/HAB-160300_ref6","volume-title":"Humira could have been a Pfizer drug","author":"Mattina","year":"2012"},{"issue":"4","key":"10.3233\/HAB-160300_ref7","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1016\/S0021-9258(18)89560-6","article-title":"Human tumor necrosis factor, production, purification, and characterization","volume":"260","author":"Aggarwal","year":"1985","journal-title":"The Journal of Biological Chemistry"},{"key":"10.3233\/HAB-160300_ref8","unstructured":"Can be downloaded at: http:\/\/hesiglobal.org\/wp-content\/ uploads\/sites\/11\/2016\/06\/Fry-for-website-APPROVED.pdf."},{"key":"10.3233\/HAB-160300_ref9","unstructured":"Can be downloaded at http:\/\/planetorbitrap.com\/download. php?filename=52d9bccd14347.pdf."},{"key":"10.3233\/HAB-160300_ref10","unstructured":"EPO Board of Appeal decision T0617\/07."},{"issue":"1","key":"10.3233\/HAB-160300_ref11","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1080\/19420862.2015.1107688","article-title":"Extending the market exclusivity of therapeutic antibodies through dosage patents","volume":"8","author":"Storz","year":"2016","journal-title":"MAbs"},{"key":"10.3233\/HAB-160300_ref12","unstructured":"UK Patents Court decision [2016] EWHC 425 (Pat)."},{"key":"10.3233\/HAB-160300_ref13","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/978-1-4615-0549-5_2","article-title":"Formulation development of protein dosage forms","volume":"14","author":"Akers","year":"2002","journal-title":"Pharm Biotechnol"},{"key":"10.3233\/HAB-160300_ref14","unstructured":"Decision [2016] EWCA Civ 780 of the England and Wales Court of Appeal."},{"key":"10.3233\/HAB-160300_ref15","unstructured":"Steffe E.K., Nannenga-Combs B. and Longsworth J.L., The impact of reformulation strategies on pharmaceuticals, Biologics Biosimilar Development, 14 March 2016."},{"key":"10.3233\/HAB-160300_ref16","unstructured":"Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: Quality issues (revision 1), EMA\/CHMP\/BWP\/247713\/2012."},{"key":"10.3233\/HAB-160300_ref18","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2147\/CEOR.S66338","article-title":"Adherence and resource use among patients treated with biologic drugs: Findings from BEETLE study","volume":"6","author":"Esposti","year":"2014","journal-title":"ClinicoEconomics and Outcomes Research: CEOR"},{"key":"10.3233\/HAB-160300_ref19","unstructured":"https:\/\/www.accessdata.fda.gov\/scripts\/opdlisting\/oopd\/ index.cfm Search Orphan Drug Designations and Approvals."},{"key":"10.3233\/HAB-160300_ref20","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2147\/CEOR.S66338","article-title":"Adherence and resource use among patients treated with biologic drugs: Findings from BEETLE study","volume":"6","author":"Esposti","year":"2014","journal-title":"ClinicoEconomics and Outcomes Research: CEOR"},{"key":"10.3233\/HAB-160300_ref22","doi-asserted-by":"crossref","first-page":"286857","DOI":"10.1155\/2013\/286857","article-title":"Off-label uses of anti-TNF therapy in three frequent disorders: Beh\u00e7et's disease, sarcoidosis, and noninfectious uveitis","volume":"2013","author":"S\u00e1nchez-Cano","year":"2013","journal-title":"Mediators of Inflammation"},{"key":"10.3233\/HAB-160300_ref23","unstructured":"Ditto."},{"issue":"6","key":"10.3233\/HAB-160300_ref24","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.5114\/aoms.2014.47827","article-title":"Tumor necrosis factor inhibitors - state of knowledge","volume":"10","author":"Lis","year":"2014","journal-title":"Archives of Medical Science: AMS"},{"key":"10.3233\/HAB-160300_ref25","unstructured":"Ditto."},{"issue":"11","key":"10.3233\/HAB-160300_ref26","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1001\/jamadermatol.2013.6678","article-title":"Adalimumab for the treatment of refractory acne conglobata","volume":"149","author":"Sand","year":"2013","journal-title":"JAMA dermatology"},{"issue":"6","key":"10.3233\/HAB-160300_ref27","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.5114\/aoms.2014.47827","article-title":"Tumor necrosis factor inhibitors - state of knowledge","volume":"10","author":"Lis","year":"2014","journal-title":"Archives of Medical Science: AMS"},{"issue":"11","key":"10.3233\/HAB-160300_ref28","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1001\/jamadermatol.2013.6678","article-title":"Adalimumab for the treatment of refractory acne conglobata","volume":"149","author":"Sand","year":"2013","journal-title":"JAMA dermatology"},{"key":"10.3233\/HAB-160300_ref29","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1749-6632.2009.05366.x","article-title":"Anti-TNF therapy restores the hypothalamic-pituitary-adrenal axis","volume":"1193","author":"Atzeni","year":"2010","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.3233\/HAB-160300_ref30","doi-asserted-by":"crossref","unstructured":"Berthold-Losleben M. and Himmerich H., Curr neuropharmacol, 6(3) (Sep 2008), 193-202.","DOI":"10.2174\/157015908785777238"},{"key":"10.3233\/HAB-160300_ref31","doi-asserted-by":"crossref","unstructured":"Taurog J.D. et al. Ankylosing spondylitis and axial spondyloarthritis, N Engl J Med 374(26) (2016), 2563-2574.","DOI":"10.1056\/NEJMra1406182"},{"key":"10.3233\/HAB-160300_ref33","doi-asserted-by":"crossref","first-page":"286857","DOI":"10.1155\/2013\/286857","article-title":"Off-label uses of anti-TNF therapy in three frequent disorders: Beh\u00e7et's disease, sarcoidosis, and noninfectious uveitis","volume":"2013","author":"S\u00e1nchez-Cano","year":"2013","journal-title":"Mediators of Inflammation"},{"issue":"6","key":"10.3233\/HAB-160300_ref34","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.5114\/aoms.2014.47827","article-title":"Tumor necrosis factor inhibitors - state of knowledge","volume":"10","author":"Lis","year":"2014","journal-title":"Archives of Medical Science: AMS"},{"issue":"11","key":"10.3233\/HAB-160300_ref35","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1001\/jamadermatol.2013.6678","article-title":"Adalimumab for the treatment of refractory acne conglobata","volume":"149","author":"Sand","year":"2013","journal-title":"JAMA dermatology"},{"issue":"15","key":"10.3233\/HAB-160300_ref36","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1056\/NEJMhle0807695","article-title":"Shifting terrain in the regulation of off-label promotion of pharmaceuticals","volume":"360","author":"Mello","year":"2009","journal-title":"N Engl J Med"}],"container-title":["Human Antibodies"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/HAB-160300","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T07:21:56Z","timestamp":1777447316000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/HAB-160300"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,20]]},"references-count":32,"journal-issue":{"issue":"1-2"},"URL":"https:\/\/doi.org\/10.3233\/hab-160300","relation":{},"ISSN":["1093-2607","1875-869X"],"issn-type":[{"value":"1093-2607","type":"print"},{"value":"1875-869X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,20]]}}}